Amperos Health vs Aspirion
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Amperos Health | Aspirion | |
|---|---|---|
| Pricing model | Not published | Contingency (pay from recoveries) · Success-based, paid from recovered revenue |
| Speed to go live | No configuration; working day one | Data feeds set up, they work inventory |
| Automation model | Autonomous agents · AI biller calls and works denials | Tech-enabled service · Attorneys and AI recover complex claims |
| Built for | Small practices, Mid-size groups, Billing companies | Enterprise systems |
| Security posture | SOC 2 Type I, HIPAA | HITRUST, HIPAA |
| Company maturity | 3 yrs (est. 2023) | 14 yrs (est. 2012) |
| Financial backing | $20.2M · Series A | PE-owned (Linden Capital Partners) |
| Named customers | None public | None public |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | None documented | None documented |
| Third-party validation | None found | KLAS / analyst cited |
Bottom line
- Pick Amperos if denials and aging A/R are piling up and you want an AI biller chasing claims from day one with no setup project.
- Pick Aspirion if you're a hospital with denials, MVA, workers' comp, or VA claims you can't work in-house and you'd rather pay only from what gets recovered.
Amperos Health
AI biller that works denials by phone and portal
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series A
- Raised
- $20.2M
What it does
- Calls payers to check status and dispute denials
- Works payer portals for claim follow-up
- Drafts and submits appeals with medical records
- Submits corrected claims
- Denial analytics and root-cause reporting
Where it's strong
- Automates the actual follow-up work, phone calls included, rather than just flagging denials for staff.
- Real volume behind the claims: over 3,000 clinical locations served and roughly $700M in annual recovered revenue across 500,000-plus claims.
- Pairs AI automation with human billing experts for complex claims instead of forcing everything through the model.
What buyers should weigh
- Founded in 2023, so it is still a young vendor for a function that touches core cash flow.
- Named reference customers are not public; ask for references in your specialty and billing system.
- Best fit is denial follow-up and recovery; it is not a full front-to-back RCM platform.
Aspirion
Complex claims and denials recovery for hospitals
- Founded
- 2012
- HQ
- Columbus, GA
- Stage
- PE-owned (Linden Capital Partners)
- Raised
- n/a
What it does
- Clinical and technical denials appeals with attorney support
- Motor vehicle accident and workers' compensation claims
- VA, TRICARE, and out-of-state Medicaid billing
- Underpayment and zero-balance review
- Aged AR resolution
- AI-assisted appeal generation and claim prioritization
Where it's strong
- Named 2025 Best in KLAS for denials management, its second consecutive year, which is rare third-party validation in this segment.
- In-house attorneys and clinicians handle payer disputes most internal RCM teams cannot staff, and it serves over 140 clients including many of the largest US health systems.
- Contingency-style pricing ties fees to actual recoveries, keeping downside risk low for the provider.
What buyers should weigh
- It is a recovery service that works claims after the fact; it will not fix the upstream registration or coding problems causing the denials.
- The company has absorbed several acquisitions (Boost Healthcare, FIRM, Continuum), so ask which team and toolset will actually work your inventory.
- Contingency fees on high-dollar complex claims add up; model the effective rate against building internal capacity.
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.